Executive Vice President, Chief Commercial Officer · BIOMARIN PHARMACEUTICAL INC (BMRN)

Jeff Ajer

A named executive officer of BIOMARIN PHARMACEUTICAL in every fiscal year CompBrief holds from FY2016 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$5,070,357

Salary $669,231Stock awards $3,094,233

FY2022: $5,457,338

5th of 6 named executive officers at Biomarin Pharmaceutical by FY2023 total.

6 named officers on file for BIOMARIN PHARMACEUTICAL, FY2023

Jeff Ajer’s pay file — $29

  • 8 fiscal years of pay, line by line
  • 23 equity grants, each cited to its filing
  • BMRN’s disclosed peer group of 14 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how BIOMARIN PHARMACEUTICAL’s whole pay program stands against its peers

  • BIOMARIN PHARMACEUTICAL’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on BMRN→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 9, 2024 (DEF 14A).

Free

Get Jeff Ajer’s full pay file as a PDF — free

More than this page: up to 10 years of Jeff’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Jeff Ajer compensation by year

BIOMARIN PHARMACEUTICAL Summary Compensation Table · all 8 fiscal years held
In US dollars, as BIOMARIN PHARMACEUTICAL reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
Salary$490,385$524,231$554,232$580,192$628,654$610,000$638,269$669,231
Bonus$0$0$0$0$0$0$0$0
Stock awards$2,316,017$2,133,048$2,146,078$4,303,656$2,696,310$2,941,280$3,357,648$3,094,233
Option awards$1,541,900$1,439,891$1,373,198$867,181$788,869$841,896$922,027$873,661
Non-equity incentive$357,750$451,560$450,240$561,600$402,600$567,300$512,775$405,000
Pension and deferred compensation$0$0$0$0$0$0$0$0
All other$16,361$19,572$21,635$31,693$20,003$24,933$26,619$28,232
Total$4,722,413$4,568,302$4,545,383$6,344,322$4,536,436$4,985,408$5,457,338$5,070,357

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: BIOMARIN PHARMACEUTICAL INC DEF 14A filed April 9, 2024, accession 0001048477-24-000058, and prior-year filings. Open the filing on EDGAR.

How this page was built: the BIOMARIN PHARMACEUTICAL INC filed document, accession 0001048477-24-000058. Every figure is read from that document and cited to the page and table it appears in. Filed April 9, 2024.

$4.7M
$4.6M
$4.5M
$6.3M
$4.5M
$5.0M
$5.5M
$5.1M
FY16
FY17
FY18
FY19
FY20
FY21
FY22
FY23
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
PSU11,940$1,151,255—
PSU10,720$1,033,622—
PSU10,110$974,806—
RSU10,110$974,806—
RSU8,955$863,441—
PSU6,440$620,945—
PSU5,970$575,627—
PSU5,970$575,627—
RSU5,360$516,811—
PSU5,060$487,885—
PSU5,060$487,885—
PSU4,290$413,642—

Per the Outstanding Equity Awards at Fiscal Year-End table in BIOMARIN PHARMACEUTICAL INC's FY2023 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 17 award rows shown.

BIOMARIN PHARMACEUTICAL’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Jean-Jacques BienaiméFormer CEO and Former Chairman of the Board$21,976,020
Alexander HardyPresident and Chief Executive Officer$17,875,236
Henry FuchsPresident, Worldwide R&D$9,660,818
C. Greg GuyerExecutive Vice President, Chief Technical Officer$5,701,119
Jeff Ajer · this pageExecutive Vice President, Chief Commercial Officer$5,070,357
Brian MuellerExecutive Vice President, Finance and CFO$4,854,192

The full BIOMARIN PHARMACEUTICAL compensation record

free company brief

This page is one person within BIOMARIN PHARMACEUTICAL's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the BIOMARIN PHARMACEUTICAL proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are BIOMARIN PHARMACEUTICAL's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Jeff Ajer's compensation dossier · One-time report. No refunds.